Granted Patent
B2
US 12,636,265 · App. 17/187,641 · Granted May 26, 2026
Compositions of complexing agents
Inventors:
Jeffrey Becker (Santa Barbara, CA); Gregg Peterson (Santa Barbara, CA); Jason Wallach (Philadelphia, CA)
Assignee:
Bexson Biomedical, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided herein are subcutaneous formulations of ketamine that are useful for treating a variety of disease and disorders. The subcutaneous ketamine formulations provided herein reduce injection site irritation and pain.
Claims (11)
1 . A pharmaceutical composition, comprising:
(i) an active pharmaceutical compound comprising a cationic ionized base; and
(ii) a complexing agent comprising a substituted cyclodextrin comprising a plurality of acidic functional groups, at least one of which acidic functional groups is a counter-anion to the cationic ionized base of the active pharmaceutical compound;
wherein a first solution consisting of (i) at a first concentration, (ii) at a second concentration, and water has a lower osmolality than a second solution consisting of (i) at the first concentration, a sodium salt of the complexing agent at the second concentration, and water, wherein the acidic functional groups of the complexing agent in the second solution are counter-anions to the sodium, thereby increasing the osmolality of the second solution relative to the first solution.
2 . A pharmaceutical composition comprising:
(i) an active pharmaceutical compound having an ionized nitrogen cation; and
(ii) a sodium salt of a substituted cyclodextrin comprising a plurality of acidic functional groups, from which sodium cations have been removed such that at least one of the plurality of acidic functional groups is a counter-anion to the ionized nitrogen cation of the active pharmaceutical compound;
wherein a first solution consisting of (i), (ii), and water has a lower osmolality than a second solution consisting of equivalent amounts of (i), (ii), and water but in which sodium cations have not been removed from (ii).
3 . An aqueous pharmaceutical composition formed by the process comprising:
removing at least one sodium of a sodium salt of a substituted cyclodextrin comprising a plurality of acidic functional groups and replacing the at least one sodium with an active pharmaceutical compound having a cationic nitrogen, the removal of the at least one sodium thereby reducing an osmolality of a first composition formed by combining the active pharmaceutical compound and the sodium salt of the substituted cyclodextrin compared to a second composition formed by combining the active pharmaceutical compound and a sodium salt of the substituted cyclodextrin in concentrations equivalent to the first composition but in which the at least one sodium has not been removed from the salt of the substituted cyclodextrin.
4 . The pharmaceutical composition of claim 3 , further comprising adding a base in a sufficient amount to neutralize the acidic functional groups of the substituted cyclodextrin.
Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 27, 2026
From: BEXSON BIOMEDICAL, INC.
To: PKX BIO, INC.
Reel/Frame 075811/0381 →
RELEASE OF SECURITY INTEREST
Recorded Apr 21, 2026
From: STEVANATO GROUP, S.P.A.
To: BEXSON BIOMEDICAL, INC.
Reel/Frame 074432/0480 →
SECURITY INTEREST
Recorded Jul 27, 2023
From: BEXSON BIOMEDICAL, INC.
To: STEVANATO GROUP, S.P.A.
Reel/Frame 064406/0164 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 19, 2021
From: BECKER, JEFFREY; PETERSON, GREGG; WALLACH, JASON
To: BEXSON BIOMEDICAL, INC.
Reel/Frame 057837/0301 →
Continuity (3)
Provisional Application
62848420
· May 15, 2019
References Cited (159)
US 4861760A
· Mazuel et al.
· 1989
[cited by applicant]
US 4911920A
· Jani et al.
· 1990
[cited by applicant]
US 5212162A
· Missel et al.
· 1993
[cited by applicant]
US 5352683A
· Mayer et al.
· 1994
[cited by applicant]
US 5403841A
· Lang et al.
· 1995
[cited by applicant]
US 6133248A
· Stella
· 2000
[cited by applicant]
US 6153746A
· Shah et al.
· 2000
[cited by applicant]
US 6605635B1
· Bai et al.
· 2003
[cited by applicant]
US 6831172B1
· Barbucci et al.
· 2004
[cited by applicant]
US 7034013B2
· Thompson et al.
· 2006
[cited by applicant]
US 20030055023A1
· Rajewski et al.
· 2003
[cited by applicant]
US 20040186075A1
· Loftsson et al.
· 2004
[cited by applicant]
US 20050153999A1
· Hu
· 2005
[cited by examiner]
US 20070083186A1
· Carter et al.
· 2007
[cited by applicant]
US 20070149479A1
· Fischer et al.
· 2007
[cited by applicant]
US 20100172917A1
· Ter Meulen et al.
· 2010
[cited by applicant]
US 20120295893A1
· Peled et al.
· 2012
[cited by applicant]
US 20130296437A1
· Young et al.
· 2013
[cited by applicant]
US 20140046064A1
· Boaretto et al.
· 2014
[cited by applicant]
US 20150150979A1
· Yates et al.
· 2015
[cited by applicant]
US 20150328335A1
· Nerurkar et al.
· 2015
[cited by applicant]
US 20170042878A1
· Fava et al.
· 2017
[cited by applicant]
US 20170181966A1
· Charney et al.
· 2017
[cited by applicant]
US 20190350881A1
· Surakitbanharn
· 2019
[cited by applicant]
US 20200384188A1
· Becker et al.
· 2020
[cited by applicant]
CN 1939298A
· 2007
[cited by applicant]
CN 111330019A
· 2020
[cited by applicant]
DE 102016014603A1
· 2018
[cited by applicant]
EP 0657176A2
· 1995
[cited by applicant]
EP 3498266A1
· 2019
[cited by applicant]
WO WO9500144A1
· 1995
[cited by applicant]
WO WO0165657A1
· 2001
[cited by applicant]
WO WO2005020929A2
· 2005
[cited by applicant]
WO WO2014121235A2
· 2014
[cited by applicant]
WO WO2017120639A1
· 2017
[cited by applicant]
WO WO2017180589A1
· 2017
[cited by applicant]
WO WO2019023770A1
· 2019
[cited by applicant]
WO WO2020232274A1
· 2020
[cited by applicant]
WO WO2022109050A1
· 2022
[cited by applicant]
WO WO2022109052A1
· 2022
[cited by applicant]
WO WO2023225113A1
· 2023
[cited by applicant]
WO WO2025111482A1
· 2025
[cited by applicant]
2020 Guidance on Captisol (“How to Solubilize a Drug with Captisol”) (2020).
[cited by applicant]
Al-Muhammed et al. In-vivo studies on dexamethasone sodium phosphate liposomes. J Microencapsul. 13(3):293-306 (1996).
[cited by applicant]
Chiang et al. An Fc domain protein-small molecule conjugate as an enhanced immunomodulator. J. Am. Chem. Soc. 136(9):3370-73 (2014).
[cited by applicant]
Chonn et al. Recent advances in liposomal drug-delivery systems. Curr Opin Biotechnol. 6(6):698-708(1995).
[cited by applicant]
Cyclodextrins used as excipients. Eur Med Agency Comm Hum Med Prod. Oct. 2017:16.
[cited by applicant]
Donnelly: Stability of Diluted Ketamine Packaged in Glass Vials. CJHP. 66(3) 2013.
[cited by applicant]
Eide et al.: Continuous subcutaneous administration of the N-methyl-D-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgia. Pain. 61(2):221-228 (1995).
[cited by applicant]
European Patent Application No. 18879075.2 European Search Report dated Aug. 4, 2021.
[cited by applicant]
Eyles: Oral Delivery and Fate of Poly (lactic acid) Microsphere-encapsulated Interferon in Rats J. Pharm. Pharmacol. 49:669-674 (1997).
[cited by applicant]
Gilotra et al.: Efficacy of intravenous furosemide versus a novel, pH-neutral furosemide formulation administered subcutaneously in outpatients with worsening heart failure. JACC: Heart Failure, 6(1), pp. 65-70 (2017).
[cited by applicant]
Graven-Nielsen et al.: Quantification of local and referred muscle pain in humans after sequential in injections of hypertonic saline. Pain, 69(1-2), pp. 111-117 (1997).
[cited by applicant]
Heinemann et al.: U-100, pH-Neutral formulation of VIAject®: faster onset of action than insulin lispro in patients with type 1 diabetes. Diabetes, Obesity and Metabolism, 14(3), pp. 222-227 (2012).
[cited by applicant]
Javid et al.: Evaluation of a Low Dose Ketamine in Post Tonsillectomy Pain Releaf: A randomized trial comparing intravenous and subcutaneous ketamine in pediatrics. Anesth Pain. 2(2):85-89 (2012).
[cited by applicant]
KETALAR Insert 2018: website https://www.nps.org.au/medicine-finder/ketalar-solution-for-injection (2018).
[cited by applicant]
Li et al. Current drug research on PEGylation with small molecular agents. Progress in Polymer Science 38:421-44 (2013).
[cited by applicant]
MacIntosh et al.: In Vitro and In Vivo Evaluation of a Sulfobutyl Ether β-Cyclodextrin Enabled Etomidate Formulation. Journal of Pharmaceutical Sciences. 93(10):2585-2594 (2004).
[cited by applicant]
Mathaes et al.: Subcutaneous injection volume of biopharmaceuticals—pushing the boundaries. Journal of pharmaceutical sciences, 105(8), pp. 2255-2259 (2016).
[cited by applicant]
Matthew et al.: Ketamine for Treatment-Resistant Unipolar Depression. CNS Drugs. 26(3):189-204 (2012).
[cited by applicant]
Mion et al.: Ketamine Pharmacology: An Update (Pharmacodynamics and Molecular Aspects, Recent Findings). CNS Neuroscience & Therapeutics. 19:370-380 (2013).
[cited by applicant]
Oshima. Continuous subcutaneous injection of ketamine for cancer pain. Can. J. Anaesth. 37(3):385-92 (1990).
[cited by applicant]
Ostro et al.: Use of liposomes as injectable-drug delivery systems; Am J. Hosp. Pharm. 46(8):1576-1587 (1989).
[cited by applicant]
PCT/US2018/061121 International Preliminary Report on Patentability dated May 19, 2020.
[cited by applicant]
PCT/US2018/061121 International Search Report and Written Opinion dated Jan. 28, 2019.
[cited by applicant]
PCT/US2020/032941 International Search Report and Written Opinion dated Sep. 4, 2020.
[cited by applicant]
PCT/US2020/032941 Invitation to Pay Additional Fees dated Jul. 7, 2020.
[cited by applicant]
Peltoniemi et al.: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy. Clin Pharmacokinet. 55(9):1059-1077 (2016).
[cited by applicant]
“PICKAR. Dosage Calculations. 1999.”.
[cited by applicant]
Puskás et al.: Sulfobutylether-cyclodextrins: structure, degree of substitution and functional performance. In Cyclodextrins: Synthesis, Chemical Applications and Role in Drug Delivery (pp. 293-320). Nova Science Publis…
[cited by applicant]
Rao. Recent developments of collagen-based materials for medical applications and drug delivery systems. J Biomater Sci Polym Ed. 7(7):623-45 (1995).
[cited by applicant]
Remington: The science and practice of pharmacy. 20th Edition. Gennaro, Eds. Lippincott Williams & Wilkins, 2003.
[cited by applicant]
Rolan et al.: The absolute bioavailability of racemic ketamine from a novel sublingual formulation. Br J Clin Pharmacol. 77(6):1011-1016 (2013).
[cited by applicant]
Stella et al.: Cyclodextrins. Toxicologic Pathology. 36:30-42 (2008).
[cited by applicant]
U.S. Appl. No. 16/874,485 Notice of Allowance dated Dec. 30, 2020.
[cited by applicant]
U.S. Appl. No. 16/874,485 Office Action dated Aug. 7, 2020.
[cited by applicant]
Wang, W.: Tolerability of hypertonic injectables. International journal of pharmaceutics, 490(1-2), pp. 308-315 (2015).
[cited by applicant]
Webster et al.: Safety and Efficacy of Prolonged Outpatient Ketamine Infusions for Neuropathic Pain: Am J Ther. 13(4):300-305 (2006).
[cited by applicant]
Abilify Package Insert. Bristol-Myers Squibb Company. Otsuka America Pharmaceutical, Inc. 1-53 (2006).
[cited by applicant]
Berge et al.: Pharmaceutical salts. Journal of Pharmaceutical Sciences 66:1-19 (1977).
[cited by applicant]
Brewster et al.: Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Deliv. Rev. 59:645-666 (2007).
[cited by applicant]
Bundgaard. Design of Prodrugs: Bioreversible Derivatives for Various Functional Groups and Chemical Entities. Elsevier (pp. 1-92) (1985).
[cited by applicant]
Chadeayne et al.: Norpsilocin: freebase and fumarate salt. Acta Cryst. E76:589-593 (2020).
[cited by applicant]
Dollo et al.: Complexation between local anesthetics and Beta-Cyclodextrin derivatives: Relationship between stability constants and in vitro membrane permeability of bupivacaine and lidocaine from their complexes. S.T.…
[cited by applicant]
Gao et al.: Controlled release of a contraceptive steroid from biodegradable and injectable gel formulations: in vitro evaluation. Pharm Res. 12(6):857-863 (1995).
[cited by applicant]
Hong et al.: Effect of cyclodextrin derivation and amorphous state of complex on accelerated degradation of ziprasidone. J. Pharm. Sci. 100(7):2703-2716 (2011).
[cited by applicant]
Jahed et al.: NMR (
[cited by applicant]
Mauri et al.: Clinical pharmacokinetics of atypical antipsychotics: An Update Clin Pharmacokinet. 57:1493-1528 (2018).
[cited by applicant]
Okimoto et al.: The interaction of charged and uncharged drugs with neutral (HP-Beta-CD) and Anionically Charged (SBE7-Beta-CD) Beta-Cyclodextrins. Pharm. Res. 13(2):256-264 (1996).
[cited by applicant]
Pastor et al.: NMR spectroscopy in coordination supramolecular chemistry: A unique and powerful methodology. Coordination Chemistry Reviews. 252(21-22):2314-2345 (2008).
[cited by applicant]
PCT/US2021/059760 International Search Report and Written Opinion dated Mar. 21, 2022.
[cited by applicant]
PCT/US2021/059760 Invitation to Pay Additional Fees dated Jan. 13, 2022.
[cited by applicant]
Schmuck et al.: A molecular flytrap for the selective binding of citrate and other tricarboxylates in water. J.Am. Chem. Soc. 127:3373-3379 (2005).
[cited by applicant]
U.S. Appl. No. 16/763,933 Final Office Action dated Feb. 3, 2023.
[cited by applicant]
U.S. Appl. No. 16/763,933 Office Action dated Aug. 19, 2022.
[cited by applicant]
U.S. Appl. No. 16/763,933 Restriction Requirement dated May 11, 2022.
[cited by applicant]
U.S. Appl. No. 17/546,880 Office Action dated Feb. 24, 2022.
[cited by applicant]
Andrade, Chittaranjan, Ketamine for Depression, 1: Clinical Summary of Issues Related to Efficacy, Adverse Effects, and Mechanism of Action. Journal of Clinical Psychiatry, vol. 78, No. 7, 852-857 (2017).
[cited by applicant]
Japanese Patent Application No. 2021-568611 Office Action dated Apr. 22, 2024.
[cited by applicant]
Javid, Mihan J., et al., Dissociative Conscious Sedation, an Alternative to General Anesthesia for Laparoscopic Peritoneal Dialysis Catheter Implantation: a Randomized Trial Comparing Intravenous and Subcutaneous Ketami…
[cited by applicant]
U.S. Appl. No. 16/763,933 Office Action dated Sep. 15, 2023.
[cited by applicant]
Abdallah, Chadi G. et al. Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin. Neuropsychopharmacology 45(6):990-997 (2020).
[cited by applicant]
Al-Muhammed, J. et al. In-vivo Studies on Dexamethasone Sodium Phosphate Liposomes. Journal of Microencapsulation 13(3):293-305 (1996).
[cited by applicant]
Andersin, R. Solubility and acid-base behaviour of midazolam in media of different pH, studied by ultraviolet spectrophotometry with multicomponent software. Journal of pharmaceutical and biomedical analysis 9(6):451-45…
[cited by applicant]
Bhalani, Dixit V. et al. Bioavailability Enhancement Techniques for Poorly Aqueous Soluble Drugs and Therapeutics. Biomedicines 10(9):2055, 1-33 (2022).
[cited by applicant]
Chemical Abstracts Service. CAS Registry: 220620-09-7. Tigecycline: pp. 1-3. Retrieved Dec. 9, 2024. Retrieved from :https://www.toku-e.com/content/product-documents/Product%20Data%20Sheet%20-%20T022.pdf#:%E2%80%94:text…
[cited by applicant]
Chemical Abstracts Service. CAS Registry No. 78755-81-4. Flumazenil. STN Entry Date Mar. 25, 2005.
[cited by applicant]
Committee for Medicinal Products for Human Use. Assessment Report Veklury International Non-Proprietary Name: Remdesivir; European Medicines Agency: The Netherlands, 2020; vol. Procedure No. EMEA/H/C/005622/0000.
[cited by applicant]
EP21895527.6 Supplementary European Search Report dated Sep. 9, 2024.
[cited by applicant]
EP21895529.2 European Search Report dated Nov. 18, 2024.
[cited by applicant]
Eyles, J E. et al. Oral Delivery and Fate of Poly(Lactic Acid) Microsphere-encapsulated Interferon in Rats. The Journal of pharmacy and pharmacology 49(7):669-674 (1997).
[cited by applicant]
Gupta, Deepak, et al., Salts of Therapeutic Agents: Chemical, Physicochemical, and Biological Considerations. Molecules 23(7):1719 (2018).
[cited by applicant]
Guthrie, J. Peter. Hydrolysis of esters of oxy acids: p K a values for strong acids; Bronsted relationship for attack of water at methyl; free energies of hydrolysis of esters of oxy acids; and a linear relationship bet…
[cited by applicant]
Hussein, Ahmad Q. et al. Alpha-Bromierung von 2-Adamantylisothiocyanat und Folgereaktionen. Chemische Berichte 112(4):1102-1109 (1979).
[cited by applicant]
Kim, Yesook. et al. Inclusion Complexation of Ziprasidone Mesylate with Beta-cyclodextrin Sulfobutyl Ether. Journal of Pharmaceutical Sciences 87(12):1560-1567 (1998).
[cited by applicant]
Krishnaiah, Yellela S.R. Pharmaceutical technologies for enhancing oral bioavailability of poorly soluble drugs. J Bioequiv Availab 2(2):28-36 (2010).
[cited by applicant]
Loftsson, Thorsteinn, and Marcus E Brewster. Cyclodextrins as functional excipients: methods to enhance complexation efficiency. Journal of pharmaceutical sciences 101(9):3019-3032 (2012).
[cited by applicant]
Loudon, Marc G. et al. Conversion of aliphatic amides into amines with [I,I-bis(trifluoroacetoxy)iodo]benzene. 1. Scope of the reaction. The Journal of Organic Chemistry 49(22):4272-4276 (1984).
[cited by applicant]
Muller, Christa E. Prodrug approaches for enhancing the bioavailability of drugs with low solubility. Chemistry and Biodiversity 6(11):2071-2083 (2009).
[cited by applicant]
Munegumi, Toratane. Where is the border line between strong acids and weak acids?. World J Chem Educ 1(1):12-16 (2013).
[cited by applicant]
Ostro, Mark J. et al. Use of Liposomes as Injectable-drug Delivery Systems. American Journal of Hospital Pharmacy 46(8):1576-1587 (1989).
[cited by applicant]
PCT/US2021/059763 International Search Report and Written Opinion dated Mar. 2, 2022.
[cited by applicant]
PCT/US2021/059763 Invitation to Pay Additional Fees dated Jan. 13, 2022.
[cited by applicant]
PCT/US2023/022578 International Search Report and Written Opinion dated Aug. 31, 2023.
[cited by applicant]
PCT/US2024/056922 Invitation to Pay Additional Fees dated Jan. 8, 2025.
[cited by applicant]
PCT/US2024/056926 International Search Report and Written Opinion dated Feb. 28, 2025.
[cited by applicant]
PCT/US2024/056926 Invitation to Pay Additional Fees dated Jan. 8, 2025.
[cited by applicant]
Poulson et al., Cyclodextrins: Structural, Chemical, and Physical Properties, and Applications, Polysaccharides, 3:1-31 (2022) Retrieved Mar. 26, 2025. Retrieved from https://www.mdpi.com/2673-4176/3/1/1.
[cited by applicant]
Rao, K Panduranga. Recent Developments of Collagen-based Materials for Medical Applications and Drug Delivery Systems. Journal of Biomaterials Science. Polymer Edition 7(7):623-645 (1995).
[cited by applicant]
Russo et al., A novel compound analgesic cream (ketamine, pentoxifylline, clonidine, DMSO) for complex regional pain syndrome patients. Pain Pract. 16(1):E14-20 (2016).
[cited by applicant]
Sapana et al., Preparation and Characterisation of β-Cyclodextrin Nebivolol Inclusion Complex, International Journal of Pharmaceutical Sciences and Research, 6(5):2205-2213 (2015) Retrieved Mar. 26, 2025. Retrieved from…
[cited by applicant]
Schonberger, B.P. et al. The Acid Hydrolysis of Cyclodextrins and Linear Oligosaccharies: A Comparative Study. Proceedings of the Fourth International Symposium on Cyclodextrins pp. 61-63 (1988).
[cited by applicant]
Stella et al.: Sulfobutylether-Beta-cyclodextrin. International Journal of Pharmaceutics. 583:119396 p. 1-7 (2020).
[cited by applicant]
Szejtli, J. Interaction of Hydrochloric Acid with Cyclodextrin. Starch-Starke 29(12):410-413 (1977).
[cited by applicant]
Thomas, Elizabeth, and Joseph Rubino. Solubility, melting point and salting-out relationships in a group of secondary amine hydrochloride salts. International journal of pharmaceutics 130(2):179-185 (1996).
[cited by applicant]
Tutunji, Maha F. et al. An in vitro investigation on acid catalyzed reactions of proton pump inhibitors in the absence of an electrophile. International journal of pharmaceutics 323(1-2):110-116 (2006).
[cited by applicant]
U.S. Appl. No. 17/981,348 Office Action dated Jun. 21, 2024.
[cited by applicant]
U.S. Appl. No. 17/981,348 Office Action dated Mar. 4, 2025.
[cited by applicant]
Wallach, Jason. et al. Three Birds, One Excipient: Development of an Improved pH, Isotonic, and Buffered Ketamine Formulation for Subcutaneous Injection. Pharmaceutics 14(3):556, 1-20 (2022).
[cited by applicant]
Wiedmann et al.: Pharmaceutical salts: Theory, use in solid dosage forms and in situ preparation in an aerosol. Asian Journal of Pharmaceutical Sciences II(6):722-734 (2016).
[cited by applicant]
Zannou et al.: Osmotic Properties of Sulfobutylether and Hydroxypropyl Cyclodextrins. Pharmaceutical Research. 18(8):1226-1231 (2001).
[cited by applicant]